Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 327-333 , April 2010

18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model

  • Shao-li Song

      Affiliations

    • Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
    • Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine (SJTUSM) & Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, 200025, China
    • ,
  • Chuang Deng

      Affiliations

    • Power Grid Telecom and Automation Center, Sichuan Electric Power Corporation, Chengdu 610041, China
    • ,
  • Ling-feng Wen

      Affiliations

    • Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
    • School of Information Technologies, The University of Sydney, NSW 2006, Sydney, Australia
    • ,
  • Jian-jun Liu

      Affiliations

    • Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
    • Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine (SJTUSM) & Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, 200025, China
    • ,
  • Hui Wang

      Affiliations

    • Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
    • Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine (SJTUSM) & Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, 200025, China
    • ,
  • David Feng

      Affiliations

    • School of Information Technologies, The University of Sydney, NSW 2006, Sydney, Australia
    • ,
  • Ching-yee Oliver Wong

      Affiliations

    • Positron Diagnostic Center and Medical Cyclotron, Department of Nuclear Medicine, William Beaumont Hospital, Royal Oak, MI 48073-6769, USA
    • ,
  • Gang Huang

      Affiliations

    • Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
    • Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine (SJTUSM) & Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, 200025, China
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China. Tel.: +86 021 63853125.

Received 20 October 2009 ,Revised 15 November 2009 ,Accepted 2 December 2009.

References 

  1. Dalton WS, Friend SH. Cancer biomarkers—an invitation to the table. Science. 2006;312(5777):1165–1168
  2. Weissleder R. Molecular imaging in cancer. Science. 2006;312(5777):1168–1171
  3. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46(6):983–985
  4. Yap JT, Carney JP, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J (Sudbury, Mass). 2004;10(4):221–233
  5. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27(4):535–541
  6. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27(3):439–445
  7. Suh C, Kang YK, Roh JL, Kim MR, Kim JS, Huh J, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49(11):1783–1789
  8. Fischman AJ, Alpert NM. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med. 1993;34(1):6–11
  9. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14(3):715–720
  10. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18F-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma—comparison with CT. Leuk Lymphoma. 2000;39(5-6):543–553
  11. Song SL, Liu JJ, Huang G, Wang ZH, Song YY, Sun XG, et al. Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model. J Nucl Med. 2008;49(2):303–309
  12. Römer W, Hanauske AR, Ziegler S, Thödtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91(12):4464–4471
  13. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, et al. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med. 2001;42(5):713–720
  14. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, et al. Prediction of short-term survival in patients with advanced non-small cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol. 2007;9(5):308–317
  15. Liu XF, Ren LR, Su GY, Liu YQ, Gu B, Dong JH. Establishment and characterization of a rabbit tumor cell line VX2. Zhonghua Bing Li Xue Za Zhi. 2005;34:661–663
  16. Shiozaki T, Sadato N, Senda M, Ishii K, Tsuchida T, Yonekura Y, et al. Noninvasive estimation of FDG input function for quantification of cerebral metabolic rate of glucose: optimization and multicenter evaluation. J Nucl Med. 2000;41(10):1612–1618
  17. Tsuchida T, Sadato N, Yonekura Y, Nakamura S, Takahashi N, Sugimoto K, et al. Noninvasive measurement of cerebral metabolic rate of glucose using standardized input function. J Nucl Med. 1999;40(9):1441–1445
  18. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging. 2007;34(1):78–86
  19. Chen K, Chen X, Renaut R, Alexander GE, Bandy D, Guo H, et al. Characterization of the image-derived carotid artery input function using independent component analysis for the quantitation of [18F] fluorodeoxyglucose positron emission tomography images. Phys Med Biol. 2007;52(23):7055–7071
  20. de Geus-Oei LF, Visser EP, Krabbe PF, van Hoorn BA, Koenders EB, Willemsen AT, et al. Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med. 2006;47(6):945–949
  21. Fang YH, Kao T, Liu RS, Wu LC. Estimating the input function non-invasively for FDG-PET quantification with multiple linear regression analysis: simulation and verification with in vivo data. Eur J Nucl Med Mol Imaging. 2004;31:692–702
  22. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging. 2007;34(11):1765–1774
  23. Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC, et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008;37(4):426–431
  24. Yasuda M, Miyazawa M, Fujita M, Kajiwara H, Iida T, Hirasawa T, et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep. 2008;19(1):111–116
  25. Li J, Yang SJ, Zhao XL, Zhang YQ, Li KN, Cui JH, et al. Significant increase of glucose transport activity in breast cancer. Zhonghua Bingli Xue Za Zhi. 2008;37(2):103–108
  26. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med. 2006;47(4):603–608
  27. Miyazawa H, Osmont A, Petit-Taboué MC, Tillet I, Travère JM, Young AR, et al. Determination of 18F-fluoro-2-deoxy-d-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50(3):263–272
  28. Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med. 1995;36(2):297–306
  29. Green LA, Gambhir SS, Srinivasan A, Banerjee PK, Hoh CK, Cherry SR, et al. Noninvasive methods for quantitating blood time–activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J Nucl Med. 1998;39(4):729–734
  30. Dimitrakopoulou-Strauss A, Strauss L. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients. Hell J Nucl Med. 2006;9(1):10–21
  31. Negoita C. Global Kinetic Imaging Using Dynamic Positron Emission Tomography Data. Phoneix, USA: Arizona State University; 2003;

☆ There are no potential conflicts of interest to disclose.

☆☆ This work was supported by National Natural Science Foundation of China (no.30830038) and the Shanghai Leading Academic Discipline Project (project no. S30203), Shanghai Science and Technology Commission's international cooperation project fund (nos. 08410702000 and 07JC14039, and grant nos. PY07002, 09XJ21032, YG08PETMS08 and SS08031).

PII: S0969-8051(09)00292-3

doi: 10.1016/j.nucmedbio.2009.12.002

Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 327-333 , April 2010

Article Tools

* Image Usage & Resolution